Related references
Note: Only part of the references are listed.Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial
Sergio Bracarda et al.
CLINICAL GENITOURINARY CANCER (2019)
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
I Stukalin et al.
CURRENT ONCOLOGY (2019)
Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
Xin Gao et al.
ONCOLOGIST (2019)
Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison
Camillo Porta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions
Aly-Khan A. Lalani et al.
EUROPEAN UROLOGY (2019)
Current and Emerging Treatments for Metastatic Renal Cell Carcinoma
Carla Cavaliere et al.
CURRENT CANCER DRUG TARGETS (2018)
Systemic therapy in metastatic renal cell carcinoma
Jens Bedke et al.
WORLD JOURNAL OF UROLOGY (2017)
Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre
Margarida Matias et al.
EUROPEAN JOURNAL OF CANCER (2017)
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard Escudier et al.
EUROPEAN UROLOGY (2017)
Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers
Thomas E. Hutson et al.
FUTURE ONCOLOGY (2017)
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
Kevin Zarrabi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma
Billy Amzal et al.
PLOS ONE (2017)
Second-line systemic therapy in metastatic renal-cell carcinoma: A review
Rohit K. Jain et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
849PREAL LIFE EFFICACY AND SAFETY OF AXITINIB (AXI) IN PATIENTS WITH RENAL CELL CARCINOMA (RCC): RESULTS FROM THE SPANISH COMPASSIONATE USE PROGRAM
P. Maroto et al.
ANNALS OF ONCOLOGY (2017)
Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy
Annalisa Guida et al.
CLINICAL GENITOURINARY CANCER (2017)
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Nicholas J. Vogelzang et al.
ADVANCES IN THERAPY (2017)
Treatment of renal cell carcinoma: Current status and future directions
Pedro C. Barata et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
L. M. A. Aparicio et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
New treatment options for metastatic renal cell carcinoma
Alejo Rodriguez-Vida et al.
ESMO OPEN (2017)
Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan
Hideaki Miyake et al.
CLINICAL GENITOURINARY CANCER (2017)
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis (vol 26, pg 2107, 2015)
S. Bracarda et al.
ANNALS OF ONCOLOGY (2016)
Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma
Brian I. Rini et al.
CLINICAL GENITOURINARY CANCER (2016)
Axitinib treatment among patients with mRCC in a US community oncology setting: A retrospective study of 135 patients.
Thomas Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma
Hideaki Miyake et al.
MEDICAL ONCOLOGY (2016)
Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis
Hai Wang et al.
ONCOTARGETS AND THERAPY (2016)
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US
Sumanta K. Pal et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
J. L. Lee et al.
ANNALS OF ONCOLOGY (2015)
An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed
Steven Sherman et al.
CLINICAL THERAPEUTICS (2015)
Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma
Viktor Gruenwald et al.
EUROPEAN UROLOGY (2015)
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
Christian Eichelberg et al.
EUROPEAN UROLOGY (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
Shukui Qin et al.
ONCOTARGETS AND THERAPY (2015)
The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer
Lili Liao et al.
CANCER GENETICS (2015)
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma
R. Elaidi et al.
ANNALS OF ONCOLOGY (2015)
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
Brian I. Rini et al.
TARGETED ONCOLOGY (2015)
Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for 2nd targeted therapy (TT) of metastatic renal cell carcinoma (mRCC) in the US: A retrospective chart review
James E. Signorovitch et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
B. Escudier et al.
BRITISH JOURNAL OF CANCER (2014)
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
Masatoshi Eto et al.
CANCER SCIENCE (2014)
Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population
Husain K. Khambati et al.
CLINICAL GENITOURINARY CANCER (2014)
Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Thomas E. Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Molecular Genetics of Clear-Cell Renal Cell Carcinoma
James Brugarolas
JOURNAL OF CLINICAL ONCOLOGY (2014)
Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules
Bradley J. Atkinson et al.
JOURNAL OF UROLOGY (2014)
Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies
Daniel Y. Heng et al.
PLOS ONE (2014)
Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: A network meta-analysis of randomised clinical trials
Henry W. C. Leung et al.
MOLECULAR AND CLINICAL ONCOLOGY (2014)
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2013)
Basic Assessment of the Older Cancer Patient
Martine Extermann
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
